blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3691675

EP3691675 - COMBINATION THERAPY FOR TREATING CANCER WITH AN INTRAVENOUS ADMINISTRATION OF A RECOMBINANT MVA AND AN ANTIBODY [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  29.03.2024
Database last updated on 14.11.2024
FormerRequest for examination was made
Status updated on  10.07.2020
FormerThe international publication has been made
Status updated on  02.03.2019
Formerunknown
Status updated on  01.09.2018
Most recent event   Tooltip31.07.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Bavarian Nordic A/S
Hejreskovvej 10A
3490 Kvistgaard / DK
[2020/33]
Inventor(s)01 / HOCHREIN, Hubertus
Haffstrasse 134
81825 Munich / DE
02 / LAUTERBACH, Henning
Meisenweg 22a
85386 Eching / DE
03 / MEDINA ECHEVERZ, Jose
Zugspitzstrasse 10
81541 Munich / DE
04 / HABJAN, Matthias
Bergmoserstrasse 7
82131 Gauting / DE
 [2020/41]
Former [2020/33]01 / HOCHREIN, Hubertus
Haffstrasse 134
81825 Munich / DE
02 / LAUTERBACH, Henning
Meisenweg 22a
85386 Eching / DE
03 / MEDINA ECHEVERZ, Jose
Willibaldstr. 32 b
80689 Munich / DE
04 / HABJAN, Matthias
Bergmoserstrasse 7
82131 Gauting / DE
Representative(s)Bendiksen, Henrik
Bavarian Nordic GmbH
Patent Department
Fraunhoferstraße 13
82152 Martinsried / DE
[2020/33]
Application number, filing date18756447.123.08.2018
[2020/33]
WO2018EP72789
Priority number, dateEP2017018782424.08.2017         Original published format: EP 17187824
[2020/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019038388
Date:28.02.2019
Language:EN
[2019/09]
Type: A1 Application with search report 
No.:EP3691675
Date:12.08.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 28.02.2019 takes the place of the publication of the European patent application.
[2020/33]
Search report(s)International search report - published on:EP28.02.2019
ClassificationIPC:A61K39/00, A61K39/12
[2020/33]
CPC:
A61K39/001106 (EP,IL,KR,US); A61K39/001152 (EP,IL,KR,US); A61K39/285 (IL,US);
A61K45/06 (EP,KR); A61K48/005 (KR); A61K48/0075 (KR);
A61P35/00 (EP,KR); A61K2039/505 (EP,IL,KR,US); A61K2039/5256 (EP,IL,KR,US);
A61K2039/53 (EP,IL,KR,US); A61K2039/54 (EP,IL,KR,US); A61K2039/55516 (EP,IL,KR,US);
A61K2039/57 (EP,IL,KR,US); A61K2039/6075 (IL,US); A61K2039/70 (IL,US);
C12N2710/24143 (EP,KR); Y02A50/30 (EP,IL) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/33]
TitleGerman:KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON KREBS MIT INTRAVENÖSER VERABREICHUNG EINES REKOMBINANTEN MVA UND EINES ANTIKÖRPERS[2020/33]
English:COMBINATION THERAPY FOR TREATING CANCER WITH AN INTRAVENOUS ADMINISTRATION OF A RECOMBINANT MVA AND AN ANTIBODY[2020/33]
French:POLYTHÉRAPIE POUR LE TRAITEMENT DU CANCER PAR ADMINISTRATION INTRAVEINEUSE D'UN MVA DE RECOMBINAISON ET D'UN ANTICORPS[2020/33]
Entry into regional phase02.06.2020National basic fee paid 
02.06.2020Designation fee(s) paid 
02.06.2020Examination fee paid 
Examination procedure16.04.2020Amendment by applicant (claims and/or description)
02.06.2020Examination requested  [2020/33]
02.06.2020Date on which the examining division has become responsible
04.04.2024Despatch of a communication from the examining division (Time limit: M04)
31.07.2024Reply to a communication from the examining division
Fees paidRenewal fee
13.08.2020Renewal fee patent year 03
13.08.2021Renewal fee patent year 04
15.07.2022Renewal fee patent year 05
05.07.2023Renewal fee patent year 06
04.07.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[I]WO2005012527  (ANGELETTI P IST RICHERCHE BIO [IT], et al);
 [ID]WO2014037124  (BAVARIAN NORDIC AS [DK]);
 [I]WO2014043518  (US HEALTH [US]);
 [I]WO2014043535  (US HEALTH [US], et al);
by applicantUS5766598
 WO0242480
 WO03048184
 US2003206926
 US6761893
 US6913752
 US2006159699
 US7247615
 US7410644
 WO2010060632
 WO2010102822
 WO2013189611
 WO2014037124
 WO2014043535
 WO2014062778
 WO2014063832
 WO2017021776
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.